Skip to content
The Nexus
DossierENTITY

Lausanne

Coverage of Lausanne in the Nexus archive.

Earliest in view: Jul 17 · 18:10 UTCMost recent: Aug 5 · 12:06 UTC
Co-mentioned in this coverage
AC Immune SAorganization1Automated Insightsorganization1Zacks Investment Researchorganization1Switzerlandplace1MindMaze Therapeuticsorganization1Zach Hendersonperson1Connect Labs by Wexfordorganization1The Pearl innovation districtplace1Charlotteplace1neurotherapeutic technologytopic1stroketopic1Alzheimer diseasetopic1Parkinson diseasetopic1
Recent coverage
  • BUSINESSAug 5 · 12:06 UTCWTOP DC
    AC Immune: Q2 Earnings Snapshot

    AC Immune SA reported second-quarter net income of $2.4 million, reversing a loss from the same period a year earlier, with revenue reaching $19.1 million. The company's shares closed at $2.27, up from $2.20 a year ago.

  • BUSINESSJul 17 · 18:10 UTCWSOC ABC CHARLOTTE
    $1B Swiss biotech establishes US headquarters in the Queen City

    Swiss biotech company MindMaze Therapeutics has established its U.S. headquarters in Charlotte's The Pearl innovation district. The company, which focuses on neurotherapeutic technology for stroke, Alzheimer disease, and Parkinson disease, opened a Patient Experience Center in May at Connect Labs by Wexford.